[
  {
    "ts": "2026-02-19T01:15:49+00:00",
    "headline": "Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation",
    "summary": "Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting. Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5%...",
    "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5afe4d13-0e39-3acb-8ce2-f12c29e9edad",
      "content": {
        "id": "5afe4d13-0e39-3acb-8ce2-f12c29e9edad",
        "contentType": "STORY",
        "title": "Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting. Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5%...",
        "pubDate": "2026-02-19T01:15:49Z",
        "displayTime": "2026-02-19T01:15:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T11:08:24+00:00",
    "headline": "Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders",
    "summary": "By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky",
    "url": "https://finance.yahoo.com/news/analysis-hims-hers-glp-1-110420310.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "47b8c1eb-0334-3de3-b42a-4ca0bcf40134",
      "content": {
        "id": "47b8c1eb-0334-3de3-b42a-4ca0bcf40134",
        "contentType": "STORY",
        "title": "Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders",
        "description": "",
        "summary": "By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky",
        "pubDate": "2026-02-19T11:08:24Z",
        "displayTime": "2026-02-19T11:08:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/c3bd5914142159b76d0ae6cd28583c25",
          "originalWidth": 800,
          "originalHeight": 450,
          "caption": "A man uses a mask while biking in this screenshot taken from an advertisement  that aired during the Super Bowl, in Vancouver, Canada, December 11, 2025.  Hims and Hers Health Inc./Handout via REUTERS",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hAU1.d0f5l_11HFuZqZnpg--~B/aD00NTA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c3bd5914142159b76d0ae6cd28583c25.cf.webp",
              "width": 800,
              "height": 450,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UVd9YfRp.Eb9Wj5SuXO7Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c3bd5914142159b76d0ae6cd28583c25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-hims-hers-glp-1-110420310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-hims-hers-glp-1-110420310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T04:33:15+00:00",
    "headline": "2 High-Flying Stocks on Our Buy List and 1 Facing Challenges",
    "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
    "url": "https://finance.yahoo.com/news/2-high-flying-stocks-buy-043315328.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "6dd84b28-07ce-3ff4-a8d3-6e8ae08e1f80",
      "content": {
        "id": "6dd84b28-07ce-3ff4-a8d3-6e8ae08e1f80",
        "contentType": "STORY",
        "title": "2 High-Flying Stocks on Our Buy List and 1 Facing Challenges",
        "description": "",
        "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
        "pubDate": "2026-02-19T04:33:15Z",
        "displayTime": "2026-02-19T04:33:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/47ca92056da206f7d44e32b861940738",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "SWBI Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/scXecdFBk2ztUEjc6WZgZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/47ca92056da206f7d44e32b861940738.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_ws9HQ1n1f6GuvfHToR_oA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/47ca92056da206f7d44e32b861940738.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-high-flying-stocks-buy-043315328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-high-flying-stocks-buy-043315328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "STRL"
            },
            {
              "symbol": "SWBI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T17:15:00+00:00",
    "headline": "Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)",
    "summary": "New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm. Additional data presented from the Phase 3 VIVID-1 (Crohn's disease) and LUCENT-3 (UC) clinical trials showed Omvoh-treated patient",
    "url": "https://finance.yahoo.com/news/patients-crohns-disease-maintained-steroid-171500571.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "4b1a9042-6502-3a4b-9c27-401abdcb74e2",
      "content": {
        "id": "4b1a9042-6502-3a4b-9c27-401abdcb74e2",
        "contentType": "STORY",
        "title": "Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)",
        "description": "",
        "summary": "New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm. Additional data presented from the Phase 3 VIVID-1 (Crohn's disease) and LUCENT-3 (UC) clinical trials showed Omvoh-treated patient",
        "pubDate": "2026-02-19T17:15:00Z",
        "displayTime": "2026-02-19T17:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/patients-crohns-disease-maintained-steroid-171500571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/patients-crohns-disease-maintained-steroid-171500571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T18:30:17+00:00",
    "headline": "Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients",
    "summary": "Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib). The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer. Lung Cancer Trial Shows Benefit The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell l",
    "url": "https://finance.yahoo.com/news/eli-lillys-experimental-cancer-drug-183017993.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "1c9738eb-d3e7-331b-96a7-a1e37133f56c",
      "content": {
        "id": "1c9738eb-d3e7-331b-96a7-a1e37133f56c",
        "contentType": "STORY",
        "title": "Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients",
        "description": "",
        "summary": "Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib). The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer. Lung Cancer Trial Shows Benefit The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell l",
        "pubDate": "2026-02-19T18:30:17Z",
        "displayTime": "2026-02-19T18:30:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/dc5921f596c42c7edd8afe19d9a4acd9",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V.w.pZ._c_I01OEsF2OG5g--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/dc5921f596c42c7edd8afe19d9a4acd9.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iC6E0N1eH5057.bB_dPBvg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/dc5921f596c42c7edd8afe19d9a4acd9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lillys-experimental-cancer-drug-183017993.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lillys-experimental-cancer-drug-183017993.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T19:08:38+00:00",
    "headline": "Is It Too Late To Consider Eli Lilly (LLY) After Its Strong Multi Year Rally?",
    "summary": "If you are wondering whether Eli Lilly at around US$1,020 per share still offers value, this article will walk through what the current price might mean for long term investors. The stock has had a mixed short term run, with a 0.5% gain over the last week, a 1.7% decline over the past month, a 5.5% decline year to date, an 18.6% gain over the last year, and a very large 3 year return that is more than triple the starting point. Recent coverage of Eli Lilly has continued to focus on its...",
    "url": "https://finance.yahoo.com/news/too-consider-eli-lilly-lly-190838789.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "194521c8-a218-3a03-99a2-17b2303f663e",
      "content": {
        "id": "194521c8-a218-3a03-99a2-17b2303f663e",
        "contentType": "STORY",
        "title": "Is It Too Late To Consider Eli Lilly (LLY) After Its Strong Multi Year Rally?",
        "description": "",
        "summary": "If you are wondering whether Eli Lilly at around US$1,020 per share still offers value, this article will walk through what the current price might mean for long term investors. The stock has had a mixed short term run, with a 0.5% gain over the last week, a 1.7% decline over the past month, a 5.5% decline year to date, an 18.6% gain over the last year, and a very large 3 year return that is more than triple the starting point. Recent coverage of Eli Lilly has continued to focus on its...",
        "pubDate": "2026-02-19T19:08:38Z",
        "displayTime": "2026-02-19T19:08:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-eli-lilly-lly-190838789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/too-consider-eli-lilly-lly-190838789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T12:16:08+00:00",
    "headline": "CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit",
    "summary": "CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its allogeneic CAR-T program zugo-cel (formerly CTX112) and outlining a strategy that includes combinati",
    "url": "https://www.marketbeat.com/instant-alerts/crispr-therapeutics-touts-zugo-cel-car-t-gains-eyes-autoimmune-expansion-at-citi-oncology-summit-2026-02-19/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "eb1cd0ab-088f-37b9-a4e6-291186980207",
      "content": {
        "id": "eb1cd0ab-088f-37b9-a4e6-291186980207",
        "contentType": "STORY",
        "title": "CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit",
        "description": "",
        "summary": "CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its allogeneic CAR-T program zugo-cel (formerly CTX112) and outlining a strategy that includes combinati",
        "pubDate": "2026-02-19T12:16:08Z",
        "displayTime": "2026-02-19T12:16:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/cf4691a045e077a356771fb4234f4817",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "CRISPR Therapeutics logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R4vSX.hqaAJoqbI1io5tIw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/cf4691a045e077a356771fb4234f4817.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YupJrDgMAdtmnmkIYdyFkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/cf4691a045e077a356771fb4234f4817.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/crispr-therapeutics-touts-zugo-cel-car-t-gains-eyes-autoimmune-expansion-at-citi-oncology-summit-2026-02-19/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-touts-zugo-cel-121608154.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "C"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T21:05:00+00:00",
    "headline": "Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention",
    "summary": "Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.",
    "url": "https://www.fool.com/investing/2026/02/19/overlooked-and-undervalued-why-novo-nordisk-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "420e58b2-d37a-3ff3-80e5-190a9113ee7f",
      "content": {
        "id": "420e58b2-d37a-3ff3-80e5-190a9113ee7f",
        "contentType": "STORY",
        "title": "Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention",
        "description": "",
        "summary": "Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.",
        "pubDate": "2026-02-19T21:05:00Z",
        "displayTime": "2026-02-19T21:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2101ee257c42eda770edd1eae74492e9",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A tape measure with a pile of pills.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jhhBVttxZImVS7Nl3B.6sw--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2101ee257c42eda770edd1eae74492e9.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3_vf6Vvk4_zi2mat7UEPCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2101ee257c42eda770edd1eae74492e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/19/overlooked-and-undervalued-why-novo-nordisk-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/overlooked-undervalued-why-novo-nordisk-210500501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]